Nanosonics Ltd (ASX: NAN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nanosonics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nanosonics Ltd (ASX: NAN)
Latest News
Growth Shares
3 stellar ASX growth shares I would buy right now
⏸️ ASX Shares
ASX 200 investor in your 40s? 3 shares to buy now
Growth Shares
3 five-star ASX 200 shares to buy in June
⏸️ ASX Shares
10 quality ASX shares to buy in June
Growth Shares
Grow your wealth with these exciting ASX mid cap shares
Growth Shares
3 outstanding ASX growth shares to invest $3,000 into today
⏸️ ASX Shares
Have $500 to invest? Then buy these 5 ASX 200 shares immediately
Growth Shares
3 high quality ASX healthcare shares to buy and hold forever
Growth Shares
How you can get very rich with ASX 200 shares
⏸️ ASX Shares
Want to invest like Warren Buffett? Buy and hold these ASX 200 shares
⏸️ ASX Shares
2 of the best ASX 200 healthcare shares to buy for the long term
Growth Shares
3 ASX growth shares to buy immediately with $3,000
Frequently Asked Questions
-
No, Nanosonics Ltd does not pay dividends at this stage.
-
Nanosonics Ltd listed on the ASX on 17 May 2007.
NAN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Nanosonics Ltd
Nanosonics Ltd (ASX: NAN) is an Australian healthcare company specialising in infection prevention.
The company has developed and commercialised an automated disinfection technology, the trophon device. Nanosonics says it represents the first major innovation in high-level disinfection for ultrasound probes in more than two decades and is fast becoming the global standard of care for ultrasound probe disinfection. The company also manufactures and distributes other related technologies.
Nanosonics is based in Sydney with sales offices in the US and Europe.
NAN Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
17 Apr 2024 | $2.81 | $-0.06 | -2.09% | 682,098 | $2.81 | $2.85 | $2.74 |
16 Apr 2024 | $2.87 | $-0.11 | -3.69% | 1,232,206 | $2.94 | $2.98 | $2.81 |
15 Apr 2024 | $2.98 | $0.10 | 3.47% | 1,183,389 | $2.87 | $2.99 | $2.87 |
12 Apr 2024 | $2.88 | $0.03 | 1.05% | 760,336 | $2.85 | $2.89 | $2.85 |
11 Apr 2024 | $2.85 | $0.02 | 0.71% | 743,530 | $2.76 | $2.86 | $2.73 |
10 Apr 2024 | $2.83 | $0.13 | 4.81% | 1,068,184 | $2.72 | $2.87 | $2.72 |
09 Apr 2024 | $2.70 | $-0.12 | -4.26% | 568,433 | $2.83 | $2.83 | $2.70 |
08 Apr 2024 | $2.82 | $0.15 | 5.62% | 9,753,149 | $2.70 | $2.85 | $2.67 |
05 Apr 2024 | $2.67 | $0.03 | 1.14% | 2,101,415 | $2.63 | $2.70 | $2.62 |
04 Apr 2024 | $2.64 | $-0.03 | -1.12% | 539,032 | $2.69 | $2.70 | $2.64 |
03 Apr 2024 | $2.67 | $-0.11 | -3.96% | 1,340,878 | $2.75 | $2.75 | $2.66 |
02 Apr 2024 | $2.78 | $0.03 | 1.09% | 772,688 | $2.75 | $2.81 | $2.71 |
28 Mar 2024 | $2.75 | $0.01 | 0.36% | 1,134,162 | $2.76 | $2.76 | $2.72 |
27 Mar 2024 | $2.74 | $0.03 | 1.11% | 544,249 | $2.68 | $2.76 | $2.68 |
26 Mar 2024 | $2.71 | $0.03 | 1.12% | 1,403,626 | $2.67 | $2.74 | $2.64 |
25 Mar 2024 | $2.68 | $0.01 | 0.37% | 1,506,399 | $2.65 | $2.74 | $2.65 |
22 Mar 2024 | $2.67 | $-0.04 | -1.48% | 568,097 | $2.68 | $2.72 | $2.67 |
21 Mar 2024 | $2.71 | $0.03 | 1.12% | 1,036,759 | $2.69 | $2.73 | $2.67 |
20 Mar 2024 | $2.68 | $0.01 | 0.37% | 1,107,463 | $2.70 | $2.70 | $2.63 |
19 Mar 2024 | $2.67 | $-0.09 | -3.26% | 1,241,767 | $2.75 | $2.77 | $2.65 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
22 Mar 2024 | Marie McDonald | Buy | 18,606 | $49,999 |
On-market trade.
|
01 Mar 2024 | Larry Marshall | Buy | 25,000 | $68,182 |
On-market trade.
|
29 Feb 2024 | Michael Kavanagh | Issued | 385,140 | $1,051,432 |
Issue of securities. 14,06,324 Rights
|
28 Feb 2024 | Steven Sargent | Buy | 36,460 | $99,742 |
On-market trade.
|
16 Feb 2024 | Michael Kavanagh | Issued | 44,054 | $131,280 |
Issue of securities. 10,21,184 Rights
|
03 Oct 2023 | Michael Kavanagh | Expiry | 286,551 | $1,154,800 |
As advised by the company. 9,77,130 Performance Rights & Service Rights, lapsed
|
29 Aug 2023 | Michael Kavanagh | Buy | 150,479 | $619,973 |
Exercise of options.
|
29 Aug 2023 | Michael Kavanagh | Exercise | 340,424 | $1,402,546 |
Exercise of options.
|
08 Jun 2023 | Michael Kavanagh | Sell | 25,000 | $120,732 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Lisa Margaret McIntyre | Non-Executive Director | Dec 2019 |
Dr McIntyre background is in strategy, particularly in the areas of medical technology and healthcare, with many years as a partner at L.E.K. Consulting in the US and Australia, where she led the Asia Pacific Health practice. Dr. McIntyre was a Director of the Garvan Institute of Medical Research for 12 years and is a Senate Fellow of the University of Sydney. She is currently a Non-executive Director of Fisher and Paykel Healthcare Corporation Limited, HCF Group, HCF Life, HCF Foundation, and Studiosity Pty Ltd. She is member of the Risk Committee and Chair of the R&D and Innovation Committee from 1st January 2023.
|
Mr David Fisher | Non-Executive Director | Jul 2001 |
Mr is a founding partner of Brandon Capital Partners, an Australian venture capital provider. Dr Fisher has more than 35 years of operating experience in the biotechnology and healthcare industry in Australia and overseas. He held senior positions with Pharmacia AB (now part of Pfizer, Inc) and was CEO of Peptech Limited. He has not held any directorships of other listed companies in the last three years. He is member of the Risk Committee and Chair of R&D and Innovation Committee till 1st January 2023.
|
Dr Larry Marshall | Non-Executive Director | Oct 2023 |
Dr Marshall brings experience to the Company. Dr Marshall is a technology innovator, physicist and business leader with over 30 years experience in leadership of technology companies. He has founded companies and innovation in Silicon Valley and Australia. Until July 2023, Dr Marshall was Chief Executive of CSIRO for 8 years. Dr Marshall lived in the United States for 26 years, where he co-founded 6 companies in a range of markets including medical device. Over the past 30 years he has served as CEO/MD of 6 companies, and Chairman of 4. He was MD, then co-Chairman of Arasor, a developer and manufacturer of integrated optical and wireless solutions, which he took public in 2006. In 2007, Dr Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specialising in Australian innovation. He has been a director of 20 private sector boards in Australia and the United States, including boards of 2 companies that were subsequently listed on the Nasdaq and on the ASX respectively.
|
Mr Michael Kavanagh | Chief Executive OfficerManaging Director | Jul 2012 |
Mr Kavanagh has more than 29 years of international commercial experience in the healthcare market, having held local, regional, and global roles in medical device and pharmaceutical industries. Before joining Nanosonics, he was Senior Vice President of Global Marketing for the medical device company Cochlear Ltd, a position he held for more than 10 years. In the last three years Mr Kavanagh has held no other directorships.
|
Ms Marie Elizabeth McDonald | Non-Executive Director | Oct 2016 |
Ms McDonald has background in corporate and commercial law, having practiced for many years as a partner at Ashurst. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010. She is member of Risk Committee.
|
Mr Steven Andrew Sargent | Non-Executive DirectorNon-Executive Chairman | Jul 2016 |
Mr Sargent had a 22-year career with General Electric and has global experience across a range of industries, including financial services and healthcare. He was Vice President and Officer of GE, a member of GE's Corporate Executive Council and CEO of GE Australia NZ. He is also member of the Risk and R&D and Innovation Committee.
|
Dr Tracey Leigh Batten | Non-Executive Director | Sep 2023 |
Dr Batten has experience of more than 30 years. During her executive career, Dr Batten was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincents Health Australia, CEO of Eastern Health, CEO of Dental Health Services Victoria and held various other clinical and medical leadership roles. Dr Batten is currently a non-executive director of Medibank Private Ltd, the EBOS Group Limited (NZX Listed), the Accident Compensation Corporation (a NZ Crown insurance scheme and investment fund) and the National Institute of Water and Atmospheric Research (a NZ Crown Research Institute). In addition, Dr Batten was previously non-executive director of Abano Healthcare Group Ltd (NZX Listed) and various other healthcare related research institutes, charities and industry and government bodies.
|
Mr Geoff Raymond Wilson | Non-Executive Director | Jul 2019 |
Mr Wilson has local and international executive leadership and director experience together spanning more than 37 years, including many years with KPMG in Australia, Hong Kong, and the USA. He has a background in finance, audit, and risk management, as well as in the Asia Pacific markets. Mr Wilson is currently a Director of TOLL Holdings Limited, HSBC Bank Australia Limited, ipSCAPE, and Sydney Symphony Limited. He is also an Ambassador for the Australian Indigenous Education Foundation. He is Chair of Risk Committee.
|
Mr Matthew Carbines | General CounselCompany Secretary | May 2023 |
-
|
McGregor Grant | Chief Financial Officer and Company Secretary |
-
|
|
Sunny Pillai | Chief Information Officer |
-
|
|
Matthew Lipscombe | Chief Marketing Officer |
-
|
|
Rod Lopez | Chief Operating Officer |
-
|
|
Jodi Sampson | Chief People and Culture Officer |
-
|
|
David Morris | Chief Strategy Officer and Regional President Asia Pacific |
-
|
|
Steven Farrugia | Chief Technology Officer |
-
|
|
Matthew Carbines | General Counsel |
-
|
|
Matthew Carbines | General CounselCompany Secretary |
-
|
|
Ronan Wright | Regional President for Europe and Middle East |
-
|
|
Ken Shaw | Regional President for North America |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 61,767,191 | 20.43% |
Citicorp Nominees Pty Limited | 44,181,499 | 14.61% |
J P Morgan Nominees Australia Pty Limited | 38,356,423 | 12.69% |
BNP Paribas Noms Pty Ltd <Drp> | 19,483,665 | 6.44% |
UBS Nominees Pty Ltd | 11,561,555 | 3.82% |
National Nominees Limited | 8,604,841 | 2.85% |
Mr Maurie Stang | 8,129,534 | 2.69% |
Mr Bernard Stang | 6,842,564 | 2.26% |
Mr Steve Kritzler | 6,489,737 | 2.15% |
Australian Foundation Investment Company Limited | 5,853,333 | 1.94% |
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 4,535,691 | 1.50% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 4,227,938 | 1.40% |
Dr Harry Hirschowitz | 2,139,090 | 0.71% |
First Samuel Ltd <ANF ITS MDA CLIENTS A/C> | 1,483,891 | 0.49% |
Mirrabooka Investments Limited | 1,335,007 | 0.44% |
Colonial First State Inv Ltd <2349414 Hofbauer A/C> | 1,200,000 | 0.40% |
BNP Paribas Noms (NZ) LTD <DRP> | 1,048,517 | 0.35% |
BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <Drp A/C> | 999,603 | 0.33% |
Invia Custodian Pty Limited <Penance A/C> | 950,000 | 0.31% |
Netwealth Investments Limited <Wrap Services A/C> | 906,627 | 0.29% |